Down-Regulated E-Cadherin Expression Is Associated with Poor Five-Year Overall Survival in Bone and Soft Tissue Sarcoma: Results of a Meta-Analysis |
| |
| Authors: | Ning Wang Yong-Lai He Li-Juan Pang Hong Zou Chun-Xia Liu Jin Zhao Jian-Ming Hu Wen-Jie Zhang Yan Qi Feng Li |
| |
| Institution: | 1. Department of Pathology, Shihezi University School of Medicine, Shihezi, Xinjiang, China.; 2. Key Laboratories for Xinjiang Endemic and Ethnic Diseases, Shihezi University and Chinese Ministry of Education, Shihezi, Xinjiang, China.; 3. Department of ICU intensive care, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China.; University of North Carolina School of Medicine, UNITED STATES, |
| |
| Abstract: | PurposeTo conduct a meta-analysis to evaluate the prognostic role of E-cadherin expression in bone and soft tissue sarcomas.MethodsThe PubMed, EMBASE, and Web of Science databases were searched using terms related to E-cadherin, sarcoma, and prognosis for all articles published in English before March 2014. Pooled effect was calculated from the available data to evaluate the association between negative E-cadherin expression and 5-year overall survival and tumor clinicopathological features in sarcoma patients. Pooled odds ratios (OR) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a fixed-effects model.ResultEight studies met the selection criteria and reported on 812 subjects. A total of 496 subjects showed positive E-cadherin expression (59.9%). Negative E-cadherin expression in bone and soft tissue sarcomas was correlated with lower 5-year overall survival (OR = 3.831; 95% CI: 2.246–6.534), and was associated with higher clinical stage (RR = 1.446; 95% CI: 1.030–2.028) and with male sex (RR = 0.678; 95% CI: 0.493–0.933).ConclusionIn the E-cadherin negative group, 5-year overall survival was significantly worse than in the E-cadherin positive group. However, further studies are required to confirm these results. |
| |
| Keywords: | |
|
|
